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Abstract
This article gives an overview of anthropological research on bioprospecting in general and of
available literature related to bioprospecting particularly in South Africa. It points out how new
insights on value regimes concerning plant-based medicines may be gained through further research
and is meant to contribute to a critical discussion about the ethics of Access and Benefit Sharing
(ABS). In South Africa, traditional healers, plant gatherers, petty traders, researchers and private
investors are assembled around the issues of standardization and commercialization of knowledge
about plants. This coincides with a nation-building project which promotes the revitalization of
local knowledge within the so called African Renaissance. A social science analysis of the
transformation of so called Traditional Medicine (TM) may shed light onto this renaissance by
tracing social arenas in which different regimes of value are brought into conflict. When medicinal
plants turn into assets in a national and global economy, they seem to be manipulated and
transformed in relation to their capacity to promote health, their market value, and their potential
to construct new ethics of development. In this context, the translation of socially and culturally
situated local knowledge about muthi into global pharmaceuticals creates new forms of agency as
well as new power differentials between the different actors involved.
Biovalue in the African Renaissance
A growing demand for herbal medicines in North America
and Europe as well as epidemics like Malaria, Tuberculo-
sis and HIV/AIDS in Sub-Sahara African have created an
expanding market for indigenous herbal medicines. Tradi-
tional healers, plant gatherers, petty traders, research insti-
tutions and private corporations have assembled around
the issues of standardization and commercialization of
local knowledge about plants. In South Africa this coin-
cides with a nation-building project, which promotes the
revitalization of local knowledge in the so called "African
Renaissance" [1]. The idea of such renaissance is as old as
the Pan-Africanist movement and its struggle for a regen-
eration of the continent after slavery and colonialism [2].
More recently, it was proclaimed by Thabo Mbeki's presi-
dential campaigns as synonymous to a "second liberation
struggle" for self-discovery, democratization and eco-
nomic development. There is reason to assume that the
transformation of so called Traditional Medicine (TM)
sheds light onto this renaissance by indicating how differ-
ent regimes of value are brought into conflict. Indeed, the
translation of socially and culturally situated local knowl-
edge into global pharmaceuticals creates new forms of
agency as well as new power differentials between corpo-
rate investors, scientists, plant gatherers, and traditional
healers. The present article alludes to the transformation
of TM in South Africa by giving an overview of key
moments in bioprospecting, the "exploration of biodiver-
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sity for commercially valuable genetic and biochemical
resources" [3]. It will thereby trace social arenas in which
plant based medicines have been assigned biovalue.
Catherine Waldby first introduced the concept of biovalue
to designate the relationship between the promotion of
health, the production of capital and the question of eth-
ics in the context of human tissue and stem cell research
[4]. It is generated through the manipulation of biological
processes in the laboratory and yields therapeutic as well
as monetary revenue. Furthermore, as emphasized by
Novas and Rose it is simultaneously commercial and eth-
ical [5]. In the present review, the notion of biovalue will
depict the assignment of value to genetic material derived
from indigenous medical plants. Although plants mark-
edly differ from human stem cells similar dynamics seem
to be at stake. Following Waldby, we are able to discern at
least three main points of relevance to bioprospecting in
the African Renaissance, emerging from a review of exist-
ing policy papers, legal frameworks, and academic
research. When medicinal plants turn into assets in a
national and global economy they become manipulated
and transformed in relation to their capacity to promote
health, their market value, and their potential to construct
a new ethics of development. Before addressing these
three aspects, I will first of all point to some anthropolog-
ical work relevant for future studies on bioprospecting in
society. I then give an overview of literature on bio-
prospecting within Social and Cultural Anthropology.
Finally, the paper will be point out how new insights on
value regimes on plant-based medicines may be gained
through further research.
Medical Pluralisms, Technology and Science
The process of enlightenment, globalization, modernity
or post-modernity has been characterized by accelerating
social change in the face of ambiguity, fragmentation and
a quest for new certainties. Human experience becomes
tangled by anonymous flows of capital, technologies,
goods, people, images and ideas that may restrain at the
same time as they may expand subjects' agency [6]. While
there is a growing number of studies about the effects of
this process at large, few concentrate on the transforma-
tion of plant-based traditional medicines and even less do
so in Africa. Teleological assumptions made by Moderni-
zation Theory have been challenged by research in Medi-
cal Anthropology. Accordingly, information and
education based on "scientific facts" do not automatically
result in a replacement of so called "traditional beliefs".
While some local medical treatments vanish over time
others may be transformed, revitalized or reinvented [7].
Furthermore, it has been documented how subjects
choose therapies and etiology eclectically, thereby gener-
ating new systems of signification [8-10]. In this sense, the
impact of biomedical science and technology results in
medical pluralisms and the hybridization of medical prac-
tice.
If this is the case with contemporary African medical sys-
tems, it is vital to analyze how the appropriation of new
practices takes place among the different actors involved
and what new significations and meanings are produced
by medical pluralism. However, biomedicine is not just
another link in a harmonic alignment of health care pro-
viders. Dominant discourses based on cosmopolitan
notions of health introduced by international develop-
ment agencies, multinational corporations and state insti-
tutions may well conflict with the ones adopted by rural
plant collectors, petty traders or traditional healers. It has
been argued that in order to reach beyond a mere docu-
mentation of medical pluralisms, the process of significa-
tion must be deciphered by a thorough analysis of power
relations [11]. These become particularly salient in the
field of property rights. The Anthropology of Law has long
addressed cultural variation in property regimes [12,13],
trends towards flexible dispute resolution instead of rights
based decision-making [14,15] and the local appropria-
tion of legal forms in multiple settings [16].
These studies have hardly been linked to research on bio-
prospecting in society and on the role of the biosciences
in the negotiation of property rights in developing coun-
tries. It has in fact long been argued that science in general
assumes a hegemonic position through the construction
of its object. Theorizing in the anthropology and sociol-
ogy of knowledge emphasizes that the externalized prod-
ucts of human activity attain the character of objectivity
through a dialectical relationship between humans and
the social world [17-19]. Ethnography has shown that
there is no straightforward trajectory from laboratory
research and the discovery of so called facts to medical
technologies and their rational implementation in the
social field [20-23]. Beyond the physical level of biomed-
ical disease, the process of signification is tied to the spe-
cific interests of the actors involved. Calling for a
suspension of a conceptual nature/culture divide ethno-
graphic studies of laboratory practice contend that arti-
facts themselves are involved in the construction of
heterogeneous actor-networks of humans and non-
human "actants" [20,24,25].
On the other hand, anthropological analysis of medicine,
science and technology also went beyond epistemological
issues and analyzed modes of commodification of life and
the emergence of new forms of biopolitical government in
the field of genetic resources derived from animals and
humans [26-28]. Frequently, the artifacts of research and
development are legitimated and disseminated along
powerful global allegiances and social networks rather
than being product of neutral reasoning based on naturalJournal of Ethnobiology and Ethnomedicine 2008, 4:9 http://www.ethnobiomed.com/content/4/1/9
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cause and effect. In this context, the ethnographic study of
pharmaceuticals and their biographies has become a
promising new field of inquiry that, however, has hardly
targeted herbal medicines [29-31]. Future research will
have to include more inquiries into the enclosure of
knowledge for the purpose of drug development con-
cerned with genetic or biochemical resources derived
from indigenous medical plants. Some relevant examples
of anthropological research done in this field are particu-
larly concerned with bioprospecting.
Bioprospecting and "Biopiracy" in International 
Perspective
To date ethnographic studies concerning the process of
bioprospecting have primarily focused on the Americas
where major bioprospecting agreements were established
between the U.S.-based International Cooperative Biodi-
versity Group (ICBG) and Latin American universities
from the early 1990s onwards. In this context, some
anthropologists started to suggest that the inclusion of
local knowledge into national and international patent
law is incompatible with local cosmologies and may ulti-
mately inflict "symbolic violence" upon indigenous cul-
tures [32,33]. Others have emphasized that these
communities are not only passive victims of globalization
but rather selectively appropriate cosmopolitan dis-
courses about intellectual property rights for the pursuit of
their own interest [34].
It has also been pointed out that the struggle for indige-
nous rights can even have racist undertones that for the
sake of ethno-national endeavors, depict culture as static
and unchanging [35]. Such essentialist understandings
often result in claims to the "copyright of culture". For
Brown, the enclosure of knowledge however, bears the
risk of putting an end to science, human progress and
even democracy [36]. In another worst-case scenario, bio-
prospecting could contribute to conflict between different
ethnic groups or even nation states that claim ownership
to a genetic resource as well as to internal social disinte-
gration of communities [37]. The latter seems to be true
especially when certain factions are externally appointed
to be representative of an imagined community although
they do not reflect the opinion of the majority of people
concerned [36,38]. The role of NGOs in this process may
vary from generating exaggerated expectations about
potential benefits through commercialization of IK to an
emphasis on its devastating effects. So-called non-profit
organizations may even foreclose rights recognition by
mediating the interest of multinational corporations [39].
NGOs can nevertheless bring entire bioprospecting pro-
grams to halt through accusations of biopiracy or theft of
IK. This may be the case even though local resource pro-
viders haven't given their mandate to do so [40]. With
regard to this problem, it has been claimed that the gov-
ernance of potentially collaborating indigenous societies
is the key to successful benefit-sharing and must therefore
be strengthened through capable authorizing institutions
as well as a "culture of responsible research" [41].
Critics within anthropology have questioned the notion
of biopiracy as non-contractual collection and use of
resources as a useful analytical category for it is itself based
on an understanding of authorship that underlies the very
expropriation of indigenous resources by powerful global
actors. From this perspective, benefit-sharing agreements
contribute to the construction of bounded communities.
Through appropriation from the public domain intellec-
tual property is extended by "closing" agricultural com-
mons whose origin in reality is ambiguous [42,43]. Cori
Hayden's analysis of a bilateral benefit-sharing agreement
between the U.S. and Mexico suggests that bio-artifacts
contain, reproduce, and represent people's interests,
thereby shaping social relationships for each plant col-
lected [44]. In this sense, bioprospecting makes "nature go
public" since it generates new audiences for scientific
"facts" among private investors and local communities
alike. The designation of benefit-recipients whether scien-
tists or local interlocutors whom they are to recruit, creates
incentives "to value their resources in ways imagined by
project founders and architects" [44,61]. At stake are new
forms of governance that produce human subjectivities
and natural objects which conceptualize themselves or
become conceptualized by idioms of the neoliberal mar-
ket.
Medicinal plants are not only passive objects of scientific
reason; from the perspective of Actor-Network-Theory
mentioned above, they attract and connect different
human and non-human actors. Through bioprospecting
in society the emergent networks are not only constructed
in relation to scientific knowledge production, but also in
relation to prospective plant producers, private investors,
and holders of local knowledge about plants. In this con-
text we can concur with Franklin in arguing that bio-
prospecting draws nature and its so-called stakeholders
into globally emergent forms of biocapital [45]. As
pointed out by Sunder Rajan biocapital is a system of
exchanges in the life-sciences that leads to an "implosion"
of epistemology and political economy. It generates a
"hype" around potential medicines that attracts venture
capital and creates a speculative marketplace [46]. As
such, it is not necessarily based on the actual needs of
patients but on the anticipation of future consumers who
eventually, may generate high profits. Before turning to
the global marketplace created through bioprospecting, I
will first of all address its relevance for the promotion of
health in South Africa more broadly.Journal of Ethnobiology and Ethnomedicine 2008, 4:9 http://www.ethnobiomed.com/content/4/1/9
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Bioprospecting and the Promotion of Health
The transformation of indigenous medical plants has
been recently seen as prerequisite for effective health pro-
motion including the reduction of poverty. Whereas
under colonialism, health and African tradition were seen
as rather contradictory, today there is a revived interest in
the way in which so-called Indigenous Knowledge Sys-
tems (IKS) can be made applicable for public health. The
World Bank's Indigenous Knowledge Program defines IKS
as "problem solving strategies for local communities" to
achieve the Millennium Development Goals, to promote
the sustainable management of resources, to enhance
health care and to fight HIV/AIDS [47]. The World Health
Organization has a particular interest in Traditional Med-
icine, the evaluation of its safety and efficacy and its inte-
gration into national healthcare systems [48]. The
emphasis on local knowledge among international devel-
opment organizations partly stems from past experience
in ineffective top-down driven technical interventions
and a general move toward a discourse on "empower-
ment" and "participation" [49]. The latter have been pro-
moted in view of reducing costs for health care in resource
poor settings by transferring more responsibility to the
target population itself. The extent to which the search for
commercially valuable genetic resources in Southern
Africa is tied to new modes of biopolitical government
through public health has not yet been addressed through
social science research. Indeed, the search for indigenous
herbal medicines in South Africa seems to be part of a
larger nation-building project called African Renaissance
which implicitly draws upon local knowledge, the life-sci-
ences, and the counties' rich biodiversity.
Lund argues that the architects of the new South Africa
draw on a long-standing tradition of using biological
analogies to interpret social phenomena and to promote
national causes. After Apartheid the government took
recourse to rhetoric around "healing the nation" using
metaphors previously used in colonial and apartheid dis-
course [50]. Currently, the promotion of South Africa's
vitality through bioprospecting takes place within a larger
project of self-discovery and the revitalization of African
culture coupled with an investment into the life-sciences.
President Mbeki, in his well-known African Renaissance
statement, emphasizes that "the colonizers sought to
enslave the African mind and to destroy the African soul",
therefore "the beginning of our rebirth as a continent
must be our own rediscovery of our soul" [51]. Since then,
much effort has been put into stimulating the contribu-
tion of IKS to health and development. The South African
IKS policy aims at promoting a positive African identity by
the affirmation of African cultural values and the develop-
ment of services provided by holders of IK, especially in
the field of Traditional Medicine. It further maintains that
the role of indigenous knowledge in the creation of eco-
nomic wealth must be strengthened and indigenous
knowledge should be "used together with modern bio-
technology in the pharmaceutical and other sectors to
increase the rate of innovation" [52]. Considering South
Africa's rich biodiversity, the connection between a
"healthy nation" and biology is metaphoric as it is mate-
rial. Roughly, 700 plant species are used and traded for
medical purpose outside the formal biomedical system
[53]. The local knowledge, including notions of health
and healing, attached to them is currently being trans-
formed.
In South Africa publicly funded research institutions have
a marked interest in the commercialization of plant-based
medicines purified of cultural and social derivates. All
major South African universities have botany or biochem-
istry departments that engage in bioprospecting activities
concerning TM; the same is true for large research institu-
tions like the Medical Research Council (MRC) or the
Council for Scientific and Industrial Research (CSIR). It is
hoped that prospecting and the commercial cultivation of
medical plants will yield new employment opportunities
at the rural level and cost-effective drugs against regionally
prevalent diseases [54]. In this context, the promotion of
health seems to be tied to the enclosure of knowledge
about plants. This enclosure however equates local
knowledge with information relevant for bioprospecting.
The National Patents Act was amended to include a defi-
nition of traditional knowledge as "knowledge that an
indigenous community has regarding the use of a biolog-
ical or genetic resource". Indeed, the cosmopolitan lan-
guage of the life-sciences favors certain aspects being
immediately compatible with analyzing plant based med-
icines in the laboratory, while neglecting others that may
still be meaningful to local producers, distributors,
patients and healers [7]. In South Africa approximately
350.000 Traditional Healers offer medicinal plants to
60–80% of the population [55]. Wreford argues that
while healers are quite interested in partnerships and
associations with biomedicine, the enthusiasm is hardly
reciprocated. They are expected to adapt to biomedicine
in a "unidirectional project" [56].
Indeed, mutual understanding between traditional heal-
ers, state officials, and scientists seems to be rather limited
[57]. Once highlighted by Ngubane [58], the distinction
between herbalist or inyanga and diviner or sangoma is
now widely endorsed by the state. For research institu-
tions inyangas are the main representatives of local knowl-
edge due to their assumed compatibility with Western
epistemology. Although patients hardly distinguish them
from sangomas, the latter have been confined to the realm
of religion and belief [57]. Such categorization seems to
deceptive considering the complex interrelationships
between the physical, the social and the spiritual world,Journal of Ethnobiology and Ethnomedicine 2008, 4:9 http://www.ethnobiomed.com/content/4/1/9
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established through African healers' diagnosis and treat-
ment [10]. This becomes salient in the concept of muthi,
which derives from the Nguni root -thi and signifies tree.
It refers to a substance or mixture of different substances
primarily derived from plant material and processed in a
way either to achieve positive effects of healing, cleansing
and protection from evil forces or negative ones of witch-
craft, misfortune and ill-health. A study of Xhosa chemists
in Eastern Cape Province by Cocks and Moller found that
almost one third of medicines were purchased for "per-
sonal well being" and "cultural purpose", like warding off
evil spirits and to bring good luck [59].
However, clear-cut distinctions between those remedies
that fall in the realm of culture and those falling into that
of life-science must be treated with caution. There are epis-
temological similarities and differences between indige-
nous and biomedical notions of herbal medicine.
Ashforth explains this issue vividly by illustrating how
from the emic point of view, muthi may be activated by
spirits, may be applied from spatial distance and does not
necessarily have to enter the body [60]. From this perspec-
tive, muthi is inherently ambiguous since it can be under-
stood either as medicine or poison according to the moral
interpretation of intentions involved in its application.
Without constructing a simple binary opposition between
"local tradition" and "global science" it is safe to say that
some interfaces and conflicts are likely to result from
divergent ideas about muthi  and its health promoting
properties which are being prospected.
The Generation of Monetary Value
With the advent of market-exchange medicinal plants, the
knowledge attached to them is not only valued for healing
but also for commercial purpose. African medicinal plants
have entered the speculative marketplace of biocapital.
The importance of investment in the "high growth" sec-
tors of biotechnology and phytomedicine have been
addressed in the founding document of the New Partner-
ship for Africa's Development (NEPAD) [61] and later
been specified by the African Biosciences Initiative [62].
Particularly in South Africa, there is a substantial market
for plant based medicines. Ten years ago plant species
traded for medical use already made up 20.000 tons of
plant material with an estimated annual value of 38 Mil.
US$ [63]. The muthi trade is mostly based on a "hidden
economy" of self-dependent plant gatherers, street ven-
dors and healers, which forms part of income generating
strategies of rural households and especially low income
women [64,65]. Considered as an untapped source for
economic development, the muthi market is difficult to
approach by state institutions and pharmaceutical compa-
nies. For successful commercialization of plant based
medicine on a national and global scale, property rights
are deemed prerequisite. The World Trade Organization's
(WTO) Agreement on Trade Related Aspects of Intellec-
tual Property Rights (TRIPS) protects inventions of legal
persons based on novelty, non-obviousness and innova-
tion. The agreement states that member parties may
exclude plants and essential biological processes from pat-
entability but obliges them to provide for the protection
of plant varieties either by patents or by the maintenance
of ex-situ plant collections or a combination thereof (Art.
27/3) [66].
One of the first efforts to establish a national collection of
biomedically valuable plants in South Africa dates back to
the 1990s when a company called Noristan Laboratories
donated a database to the University of Cape Town's Phar-
macology Department. The Traditional Medicines Project
(TRAMED) was subsequently criticized by an US based
group called "People's Health Alliance Rejecting Medical
Authoritarianism Prejudice and Conspiratorial Tyranny"
(PHARMAPACT) for illegitimately disclosing local knowl-
edge. New information and communication technologies
enabled the NGO to spread the concern of a TM sell-out.
Militant accusations and some media coverage around
"biopiracy" culminated in the late 1990s when the South
African Medicines and Medical Devices Regulatory
Authority Act was authorized (MDRA 1998) [67]. For the
first time all medicines, including TM had to be registered
with the Medicines Control Council and could only be
sold with disclosure of their ingredients. While some
argued that the regulation of TM would be vital for the
safety and efficacy of treatments, others maintained that
TM could not be evaluated in biomedical terms. Further-
more, it was feared the new legislation served the more
subtle purpose of controlling economic revenues gained
from plant medicines. Sipho Mndaweni, former president
of the Interim Coordinating Committee of Traditional
Practitioners in South Africa (ICCTP), was one of the first
to complain that "traditional healers and vendors may
end up being squeezed out of the market", insisting that
"we won't see a cent of the vast profits they will make,
even though people will buy these goods thinking it's the
same as what we do" [68]. Although submissions were
directed to Parliament to claim control over the trademark
Traditional Medicine, the trend since is largely driven by
attempts to standardize TM in biomedical terms [69].
Internet-platforms like TRAMED have to some extent sub-
stituted  sangomas  and  inyangas  as primary source of
knowledge about endemic medical plants as candidates
for bioprospecting.
In fact, several Southern African plant varieties that have
been previously patented in North America and Europe
are now being protected under TRIPS. An exemplary case
is the patenting of a purified extract from Harpagophytum
procumbens, assigned by the German company Finkelberg,
a leading producer of plant extracts for the pharmaceuticalJournal of Ethnobiology and Ethnomedicine 2008, 4:9 http://www.ethnobiomed.com/content/4/1/9
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industry. The substance may be used for the preparation
of medications for the treatment of asthma, inflammatory
conditions of the gastro intestinal tract or diseases of the
rheumatic type [70]. The healing properties of the plant
that came to be known as devil's claw have been recog-
nized by the Khoisan people of the Kalahari long before
they were primarily divulged to a German colonial soldier
in the late 19th century. However, the originators of the
medicine were neither addressed through patent negotia-
tions nor did they benefit from the large commercial suc-
cess of the drug in Germany where it turned into the third
most frequently used natural drug of all. Currently, corpo-
rations like Ratiopharm or Hexal offer a 50 g extract of
devil's claw in tablet form for roughly 25 Euros. According
to the German Church Development Service San plant
gatherers in Namibia are at best paid 30–40 cents per kil-
ogram of dried tubers, while others are hired for no other
payment than food and drink [71].
A more recent case of controversy concerns the patenting
of extracts from Pelargonium sidoides and Pelargonium reni-
forme by the company ISO Arzneimittel. The former is pre-
dominantly found in the South Africa's Eastern Cape
while the latter is endemic throughout the cape regions
and KwaZuluNatal as well as to Lesotho. There is growing
bioscientific evidence of the antibacterial, antifungal and
antitubercular activity of plant extracts [72]. Although Pel-
argomium has been used as medicinal plant for a variety of
infectious disease by Xhosa, Zulu and Basotho people for
many generations, this was neither acknowledged by the
new patent holders nor by South African companies
which market the drug already for more than a decade
without claims to intellectual property. Officials from ISO
Arzneimittel still hold that they won't challenge their
South African competitors. However, according to the
African Centre for Biosafety, no ABS agreement has been
established in the forefront of the two patents, granted in
2003 and 2005, respectively [73]. So far, local resource
providers have seen little benefit of bioprospecting, not
only in the case of Pelargonium which is commonly used
to treat HIV related infections in the region.
An assessment of the overall use of biological resources in
South Africa conducted by the South African Biodiversity
Institute (SANBI) found that permits were mostly applied
for the collection of biological resources for "research pur-
pose". However, frequently collectors did not participate
in the "drawing up" of Material Transfer Agreements or
Memoranda of Understanding. About 50% of the
resource suppliers reported that there was no mechanism
to share benefits; the other 50% claimed to have received
some incentives like immediate cash or copies of reports
[74]. The above mentioned examples may indicate a
failed African Renaissance since the "re-discovery" of the
medicines seems to have neither added value to economic
development nor led to enhancement of health care in the
region. To date, there is little data available on the impact
of bioprospecting on "hidden economies" in South Africa.
In how far the generation of surplus and the assignment
of monetary value to plant-based medicines is something
new for plant gatherers and healers as well as for bioscien-
tist still remains to be seen. The impact of biocapital on
moral economies of reciprocal gift exchange and/or redis-
tribution which might still be prevalent in rural regions
has not been paid much attention either.
The Generation of Ethical Value
We have to take cognisance of the fact that the interrela-
tions between the different actors in a global marketplace
are complex and cannot be understood merely in terms of
exclusion and repression. Apart from the generation of
neo-colonial-like power relations the search for commer-
cially valuable biogenetic or biochemical resources also
includes the generation of an "ethics of sustainable devel-
opment" and a fragmentation of sovereignty. From the
beginning of the 1990s onwards, the assignment of eco-
nomic value to biological resources has come to be seen
as prerequisite for effective biodiversity conservation. In
deed, an ethics of biodiversity conservation through
assignment of economic value to plants is as old as the
idea of bio- or chemical prospecting itself [3]. From this
perspective, potential profit extracted from the commer-
cialization of rare species to be encountered in resource
rich countries provides an incentive to halt the destruction
of their natural habitats [75]. Resource providers also
started to struggle for shares in revenues gained by multi-
national corporations based on local knowledge about
plants. In this context, fair bioprospecting was envisaged
as a tool for sustainable development and community
participation (Reid et al. 1993) [76]. The International
Undertaking on Plant Genetic Resources [77] that for-
merly declared biodiversity to be the common heritage of
human kind was abandoned with the introduction of the
UN Convention on Biological Diversity.
It is well know that CBD grants nation states autonomous
rights over genetic resources on their territory and recog-
nizes collective rights of indigenous communities, which
must be protected by so called Access and Benefit-Sharing
(ABS) agreements. Local stakeholders of a certain resource
have to be informed about bioprospecting activities, must
give their formal consent to it and have to be compen-
sated if future revenues are to be achieved (Art. 8, 16, 19)
[78]. In turn, local resource providers have to commit
themselves to biodiversity conservation. In South Africa
this framework was finally adopted by the implementa-
tion of the National Environmental Management Biodi-
versity Act [79]. Applicants for patents must specify if their
inventions are derived from indigenous biological
resources or traditional use, which means the way inJournal of Ethnobiology and Ethnomedicine 2008, 4:9 http://www.ethnobiomed.com/content/4/1/9
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which or the purpose for which an indigenous commu-
nity uses the resource in question. Subsequently, fair pub-
lic-private partnerships between communities, state
research institutions and pharmaceutical companies are
envisioned.
There have been calls to reconsider market-oriented con-
servation in South Africa despite negative evidence from
abroad [80]. In terms of biodiversity, the country is still
one of the richest on earth. However, due to the rising
demand for medical plants and the shrinkage of habitats,
many species are already facing local extinction. It is
assumed that almost all medical plants available in urban
markets in South Africa are harvested directly in their nat-
ural habitat, mostly in an unsustainable manner [63]. In
order to enhance biodiversity conservation, some ecolo-
gists are calling for large scale cultivation programs [81].
Regionally there seems to be a growing harvesting pres-
sure to meet the demand in metropolitan centers. Several
authors call for an overall cooperation in conservation
strategies considering the socio-economic realities of local
consumers of these medicines and those who depend on
the muthi trade for their livelihoods [82]. Associated with
the new interest in medicinal plants is not only an ethics
of biodiversity conservation, but also an ethics of develop-
ment similarly linked to the assignment of monetary
value. It seems that the development of herbal medicines
for regionally prevalent diseases is less relevant for such
assignment.
The MRC with its program on traditional medicines
against Malaria, Tuberculosis and AIDS-related infections
still draws relatively little attention from potential private
investors. There is however considerable interest in drugs
that target North American and European life-style dis-
eases. The Council for Scientific and Industrial Research
has been successful in attracting several companies for the
development of an appetite suppressant derived from the
Hoodia cactus also used by the Khoisan. In 1995, the
active substance named P57 encountered in the plant was
patented by the CSIR. Six years later, a license to exploit
the patent was granted to the UK based company Phytop-
harm [83]. At the same time the San represented by the
Working Group of Indigenous Minorities in Southern
Africa (WIMSA), the South African San Council, and the
San Institute of South Africa (SASI) claimed San owner-
ship to the medicine. The NGOs constructed a body of
delegates that represented the San "community" and pro-
moted negotiations with the CSIR. In 2003, the parties
signed a benefit-sharing agreement that grants the CSIR
and its partners the exclusive right to exploit the patent
but enables the San to receive a six per cent share of the
financial benefits received by the research institution from
its private partners. In the case of success, approximately
0.03 percent to 1.2 percent of net sales of the product are
entering a trust fund shared among the San Councils of
Namibia, Botswana and South Africa [84]. The drug is cur-
rently in its last phase of clinical trials before being even-
tually distributed as a food supplement by the UK based
multinational Unilever. Rachel Wynberg, board member
of the Cape Town-based NGO Biowatch conceives the
ABS agreement as a "historical breakthrough" although
"there is a need for a more holistic, innovative and ethical
approach to biodiversity commercialization beyond the
models currently touted" [83,15].
It has been claimed that unbalanced power relations
between holders of local knowledge about muthi and sci-
entists must be overcome to contribute to real social inno-
vation through bioprospecting in South Africa. From this
perspective, effectiveness will depend as much on a more
equitable "inward stretch" to endogenous knowledge as
on "outward reach" to global sources [85]. Until recently,
the testing of biological activity of crude extracts and the
isolation of compounds received much more attention
than the interaction between plants and people, folk tax-
onomies, plant-related mythology, and pre-colonial plant
use [86]. The extent to which an ethics based on market-
principles in Post-Apartheid South Africa is able to bridge
the gap between different values accorded to medicinal
plants is far from being evident yet.
Conclusion
The process of bioprospecting involves a double transla-
tion of knowledge from traditional healers about plant
based medicines and spells (muthi) into patentable scien-
tific knowledge about chemical compounds and back
again in terms of new property regimes introduced
through Access and Benefit-Sharing (ABS) agreements. In
this process, herbal medicine becomes an asset which is
manipulated and transformed in relation to its capacity to
promote health, its market value, and its potential to con-
struct a new ethics of development. Property rights on
muthi become transformed through local communities,
state, and corporate interests and, on the other hand, also
generate new institutions, alliances and discourses. The
above mentioned examples indicate a synchronicity of the
exploitation of local medical resources based on clear-cut
sovereign power relations and more flexible ones in
which actors and institutions of different social, ethnic
and organizational strata are aligned in the same network
of mutual interest. Traditional healers and San communi-
ties challenge their share in the economy of values and
adopt new property regimes on their own. However,
under the label of empowerment and participation which
adds ethical value to state institutions and multinational
corporations, still lurk historic power differentials
between North and South as well as between scientists,
holders of local knowledge and resource providers. In the
alignment of actors and actants, the South African stateJournal of Ethnobiology and Ethnomedicine 2008, 4:9 http://www.ethnobiomed.com/content/4/1/9
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still holds a hegemonic position and is drawn between the
revitalization of TM as part of an identity politics that
makes up for the impudence towards local knowledge in
the past, on the one hand, and the interest in marketable
culture on the other.
The World Trade Organization (WTO) and the Agreement
on Trade Related Aspects of Intellectual Property Rights
(TRIPS) do not recognize collective rights based on cul-
ture. While this is inconsistent with the CBD, currently,
still surprisingly little is known about how rights of own-
ership and control of IK are actually negotiated in every-
day transactions between scientists, pharmaceutical
companies, traditional healers and local communities. By
following a particular muthi and its plant ingredients from
specific rural collection or cultivation sites to the labora-
tory and back again, ethnographic studies would be able
to identify how, in actuality, value is conceptualized
among the different stakeholders, how rights to owner-
ship are negotiated between them and what consequences
this has for the promotion of a more equitable sharing of
power and knowledge in the proclaimed African Renais-
sance. Such an analysis would certainly start with an emic
view on regimes of value among plant collectors and petty
traders. Given that existing studies show that women are
primarily involved in plant harvesting in rural areas, it is
important to disclose how gender relations relate to the
"hidden" muthi economy. Whether evolving cultivation
projects challenge the economic survival of low income
women and their families or if they have a positive impact
on poverty reduction remains to be seen.
Several Anthropologists pointed out that the attempt to
copyright culture by particular fractions or organizations
at the expense of others might contribute to the schism of
communities and fuel the establishment of ethnic bound-
aries. The granting of rights on the basis of ethnicity
uncomfortably reminds us of Apartheid ideology. In fact,
the well-intentioned benefit-sharing efforts promoted by
the CBD depict a static and essential image of local culture
by assuming bluntly that neo-liberal property regimes
could be applied universally. While the convention
addresses the misappropriation of local knowledge, it also
generates new power differentials. Local medical knowl-
edge cannot be confined to clear-cut ethnic boundaries
due to well-documented dynamics of diffusion and
exchange between different identity groups. To date it is
not quite clear if the establishment of "trust funds" will
ban such dynamics. It will be of special interest to docu-
ment how far ABS agreements are contributing to a revi-
talized codification of local knowledge alongside ethnic
boundaries and/or in relation to different types of healers
and their adjunct organizations. Since there are no frame-
works for assuring the representativeness of healers or
other stakeholders in negotiations and ABS agreements,
there is also great potential for conflict between the
included and the excluded parties. The discrimination
between inyangas in terms of pure herbalists and sangomas
in terms of spiritual practitioners may contribute to rival-
ries as the latter become excluded from evolving power/
knowledge networks. Future research will have to pay spe-
cial attention to their strategies and tactics to enclose and
protect knowledge. Indeed, it is hardly known how far
bioprospecting in South Africa requires healers and local
plant providers to re-conceptualize values accorded to
medicinal plants, particularly in the face of new property
rights.
Apart from concerns with the knowledge creation process
underlying patenting, it becomes increasingly important
to address the ethical dimension of separating biochemi-
cally relevant information from muthi and the context in
which it is entwined. Biovalue can only be assigned
through translation, which involves the transformation of
muthi  to standardized scientific knowledge capable of
being turned into intellectual property. It still remains to
be addressed how value regimes, tied to locally situated
social and cultural actors and actants that come with the
substance(s), are concealed step by step through technol-
ogy. Anthropological studies on bioprospecting in South
Africa will have to consider the entanglement of the very
scientific research institutions in particular cultures and
societies. The institutions involved in bioprospecting are
about to transform organizational structures and proc-
esses in accordance with the values assigned to the subject
of study. This is likely to transform knowledge production
and reproduction itself. One of the biggest challenges in
this respect will be to analyze how market-oriented
research transforms the very sciences of ethnobotany, eth-
nobiology and ethnopharmacology. How do scientists
themselves mediate their new role as businessmen, on the
one hand, and as ethical arbitrators in access and benefit-
sharing endeavors on the other? What impact has the
search for commercially valuable and ethically appropri-
ated resources on the topics chosen or the findings
obtained in the laboratory? Finally, the problem of how to
share, with whom and on what basis may turn into a mat-
ter of informal decision-making based on an ethics
directed by the neo-liberal market.
The extent to which the transformation of regimes of
value on medicinal plants promotes, facilitates or prohib-
its an African Renaissance remains to be seen. One of the
myths generated in its context is the value accorded to bio-
prospecting as technique to simultaneously enhance the
health of the 'previously' disadvantaged, to reduce pov-
erty, to help develop a "positive" African identity, and to
protect the natural environment. While there are indica-
tors for its failure, these will have to be addressed more
thoroughly by empirical research to come. Ten years afterJournal of Ethnobiology and Ethnomedicine 2008, 4:9 http://www.ethnobiomed.com/content/4/1/9
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the announcement of the new nation-building project the
(bio)prospect for a renaissance through so-called Tradi-
tional Medicine has neither met the high expectations of
its supporters nor entailed the devastating effects of its
opponents.
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